Chickenpox Vaccine Industry Outlook 2025-2029: Market Set to Cross $4.82 Billion Milestone

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Chickenpox Vaccine Market Size By 2025?
The market size for the chickenpox vaccine has seen a significant increase in the past few years. The expected growth is from $3.57 billion in 2024 to $3.76 billion in 2025, experiencing a compound annual growth rate (CAGR) of 5.5%. Factors such as vaccine development, regulatory approvals, disease prevalence, vaccination policies, and public health endeavors have contributed to the growth during the historical period.

How Big Is the Chickenpox Vaccine Market Size Expected to Grow by 2029?
In the coming years, the chickenpox vaccine market is projected to experience robust growth, with its size expected to reach $4.82 billion in 2029, developing at a compound annual growth rate (CAGR) of 6.4%. This growth during the forecast period can be credited to factors such as the trust and perception of the public, readiness for pandemics, research and development efforts, increasing demand in emerging markets, and the growth of healthcare infrastructure. The forecast period will also witness key trends like educational campaigns about vaccines, monitoring for adverse events, strategies for pricing vaccines, innovative breakthroughs, and the application of artificial intelligence.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

Which Key Market Drivers Powering Chickenpox Vaccine Market Expansion and Growth?
The growth of the chickenpox vaccine market is anticipated to be fuelled by the increasing instances of chickenpox disease. Defined as a severe condition resulting from the varicella-zoster virus (VZV), chickenpox disease primarily manifests in the form of an irritating, fluid-filled rash. As instances of chickenpox escalate, so does the need for varicella vaccine immunization, contributing to the growing demand for chickenpox vaccines. A report issued by the American biomechanics library, the National Library of Medicine (NLM), in October 2023 showcased a study that observed GP consultations for chickenpox from September 2016 to December 2022. The results revealed an average weekly rate of 3.4 per 100,000 individuals in England, usually peaking between the 13th and 15th weeks each year. The Covid-19 pandemic disrupted these regular peaks, likely due to the implementation of social distancing and lockdowns. Despite this, 2022 saw a discernable increase in consultation rates among children below 1 year, compared to the years before the pandemic, suggesting a shift in transmission patterns. As such, the increasing occurrence of chickenpox disease is propelling the growth of the chickenpox vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8581&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Chickenpox Vaccine Market?
The chickenpox vaccine market is increasingly experiencing a trend where novel drug developments are becoming increasingly prevalent. To maintain their market positions, primary companies are engaging in the production of unique drugs that exhibit enhanced efficacy, next-gen derivatives, and other variations. For example, in November 2022, a China-based firm known for specializing in vaccine research, development and production-Sinovac Biotech Ltd.- announced that its live attenuated chickenpox (varicella) vaccine received prequalification from the World Health Organization (WHO). This is the first varicella vaccine globally to attain such certification. The vaccine's source is the Oka strain and is produced using SINOVAC's exclusive Human Diploid Cell (SV-1 strain). To create this cell, the virus is cultivated, harvested, stabilizers are added, and it is then freeze-dried. An efficacy trial for phase III revealed that the seroconversion rate within the vaccine-embedded group of children, ranging from 1 to 12 years old, stood at 97.1%. The vaccine demonstrated an efficacy rate of 87.1% against varicella and 89.2% against breakthrough varicella. Furthermore, the vaccine provides 100 percent protection against both mild and severe conditions.

What Are the Emerging Segments in the Chickenpox Vaccine Market?
The chickenpox vaccine market covered in this report is segmented -

1) By Vaccine: Monovalent Varicella Vaccine, Combination Varicella Vaccine
2) By Application: Mumps, Measles, Rubella, And Varicella Immunization, Herpes Zoster Immunization, Chickenpox Vaccination
3) By End-Users: Hospitals, Clinics, Other End-Users

Subsegments:
1) By Monovalent Varicella Vaccine: Live Attenuated Varicella Vaccine
2) By Combination Varicella Vaccine: Measles, Mumps, Rubella, And Varicella (MMRV) Vaccine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8581&type=smp

Who Are the Global Leaders in the Chickenpox Vaccine Market?
Major companies operating in the chickenpox vaccine market include Merck & Co., Sanofi Pasteur, Takeda Pharmaceutical Company Limited, CSL Limited, Pfizer Inc., Seqirus, Serum Institute of India Pvt. Ltd., Bharat Biotech, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co., Ltd., Chongqing Zhifei Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., Adimmune Corporation, Biological E. Limited, Walvax Biotechnology Co., Ltd., Zydus Cadila, Indian Immunologicals Ltd., Panacea Biotec Ltd., Bio Farma, PT Kalbe Farma Tbk, CanSino Biologics

Which are the Top Profitable Regional Markets for the Chickenpox Vaccine Industry?
North America was the largest region in the chickenpox vaccine market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chickenpox vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8581

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.